-
08-0413
The East China medicine profits the medicine to change the growth to be clear
所属栏目: Medicine 关注热度: ℃ 出处: 网络 -
Published Date:2008-01-28 The East China medicine profits the medicine to change the growth to be clear about Corporation is the medicine enterprise which is characteristic in the pharmaceutical industry and the medicine commercial aspect, is also the Zhejiang area medicine main item. The company pharmaceutical industry product had the obvious characteristic and the good growth potential, grows 145.19% compared to the same period last January to September net profit, realized each income 0.264 Yuan, but last year in the fourth quarter will welcome the company to sell the busy season, simultaneously, the real estate service will also settle accounts the part, the product concentrates, in the immunity inhibitor, diabetes treated in the medicine and the digestive tract medication, the growth prospect was good, specially took the domestic immunity inhibitor profession the main item, in the future will grow the prospect to be broad. At present company product scale big , had 4 hundred million varieties, produce market competitive ability has been strong, the technique content is high, in the market the competitor are few. in addition, the company dedicated organ transplanting domain faculty medication, argues vigorously all applies drugs specially covers completely, takes the immunity inhibitor domain the domestic Leading enterprise, the company profits the medicine to change explicitly, the principal work swift growth, the estimate value comparison security, estimated at present the East China medicine in 2007 and in 2008 each income respectively is 0.38 Yuan and 0.50 Yuan, 2008 to 2010 every year will maintain above 30% grows, the endogenetic growth determination and the superiority are obvious, in the present institutional investor enlarges under the background which increases to the medicine tectonic plate holds, at present this underestimated obviously, has the long-term investment value.
发表评论
















- 评论 (0)
- 版权声明
此页仅显示最新5条评论,点击查看全部